CD4 and intrahepatic cholangiocarcinoma: Linear multilevel models were performed to estimate pre-treatment CD4 depletion rate in both Group A and Group B. There was high heterogeneity of CD4 depletion rate among patients, with ICC ranging between 51% and 89% (Table 2).